A systematic cochrane review of corrector therapies (with or without potentiators) for people with cystic fibrosis with class II gene variants (most commonly F508DEL)

Paediatr Respir Rev. 2021 Jun:38:33-36. doi: 10.1016/j.prrv.2021.03.001. Epub 2021 Mar 11.

Authors

K W Southern¹, J Murphy¹, I P Sinha¹, S J Nevitt²

Affiliations

¹ Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.
² Department of Health Data Science, University of Liverpool, Liverpool, UK.

PMID: 33875358
DOI: 10.1016/j.prrv.2021.03.001

No abstract available

MeSH terms

Aminophenols / therapeutic use
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis* / drug therapy
Cystic Fibrosis* / genetics
Genes, MHC Class II*
Humans
Mutation

Substances

Aminophenols
Cystic Fibrosis Transmembrane Conductance Regulator